Tumor Agnostic TRK Inhibitor Therapy and NTRK Fusion Testing: Experts Answer Clinician Questions

In this episode, George D. Demetri, MD; Alexander Drilon, MD; and Pashtoon Kasi, MD, answer questions about NTRK fusion testing and TRK inhibitor therapy for patients with advanced solid tumors, with topics including:

• Best practices in testing for NTRK fusions in solid tumors
• Optimal use of approved TRK inhibitors
• Key adverse events with TRK inhibitors and management strategies
• Emerging next-generation TRK inhibitors and their potential use in managing resistance to first-generation agents

Presenters:

George D. Demetri, MD
Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics  
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, New York

Pashtoon Kasi, MD
Assistant Professor
College of Medicine and Oncology
Holden Comprehensive Cancer Center
University of Iowa
Iowa City, Iowa

Content based on an online CME program supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc. and Genentech.

Link to full program: https://bit.ly/2PN0BWh

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.